ProCE Banner Activity

Expanding Approved CAR T-Cell Therapy Treatment Options for Patients With Lymphoma

Clinical Thought
With the approval of lisocabtagene maraleucel, another CAR T-cell therapy option is now available for patients with relapsed/refractory lymphomas. Review this expert commentary on how to incorporate this agent into your practice.

Released: March 12, 2021

Expiration: March 11, 2022

Share

Faculty

Jeremy S Abramson

Jeremy S Abramson, MD, MMSc

Director, Center for Lymphoma
Mass General Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Medical College of Wisconsin in partnership with Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Kite Pharma

Faculty Disclosure

Primary Author

Jeremy S Abramson, MD, MMSc

Director, Center for Lymphoma
Mass General Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Jeremy S. Abramson, MD, MMSc, has disclosed that he has received consulting fees from AbbVie, Allogene, AstraZeneca, BeiGene, Bluebird, C4 Therapeutics, Celgene, EMD Serono, Genentech, Incyte, Karyopharm, Kite, Morphosys, and Novartis.